Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Liabilities and Shareholders Equity (2021 - 2025)

Historic Liabilities and Shareholders Equity for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $13.4 million.

  • InMed Pharmaceuticals' Liabilities and Shareholders Equity rose 2767.27% to $13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.7 million, marking a year-over-year decrease of 820.95%. This contributed to the annual value of $15.6 million for FY2025, which is 3177.98% up from last year.
  • As of Q3 2025, InMed Pharmaceuticals' Liabilities and Shareholders Equity stood at $13.4 million, which was up 2767.27% from $15.6 million recorded in Q2 2025.
  • InMed Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $19.4 million during Q4 2021, with a 5-year trough of $8.5 million in Q4 2024.
  • In the last 5 years, InMed Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $14.1 million in 2023 and averaged $13.8 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first crashed by 4426.72% in 2024, then soared by 3177.98% in 2025.
  • InMed Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $19.4 million in 2021, then fell by 12.71% to $16.9 million in 2022, then fell by 9.84% to $15.3 million in 2023, then tumbled by 44.27% to $8.5 million in 2024, then soared by 57.15% to $13.4 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $13.4 million for Q3 2025, versus $15.6 million for Q2 2025 and $9.3 million for Q1 2025.